Effects of entecavir on serum HBV DNA load and transformer growth factor-β(1) in patients with chronic hepatitis B.
- Author:
Han XIAO
1
;
Chenbin MA
;
Lixia ZHANG
;
Yongyan LUO
;
Yizhengze LIU
;
Jie SHAO
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antiviral Agents; therapeutic use; DNA, Viral; blood; Guanine; analogs & derivatives; therapeutic use; Hepatitis B virus; drug effects; Hepatitis B, Chronic; blood; drug therapy; virology; Humans; Middle Aged; Serum; metabolism; Transforming Growth Factor beta1; blood; Viral Load; Young Adult
- From: Journal of Southern Medical University 2012;32(4):589-592
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the changes in serum hepatitis B viral load (HBV DNA) and transformer growth factor-β(1)(TGF-β1) in patients with chronic hepatitis B after entecavir treatment and evaluates the therapeutic effect of entecavir.
METHODSSixty-three patients with chronic hepatitis B were randomly assigned into entecavir group (n=33) and control group (n=30). The entecavir group consisted of 9 mild, 17 moderate, and 7 severe cases, all treated with oral entecavir (0.5 mg daily) and general hepatoprotective drugs; the control group, consisting of 13 mild, 12 moderate and 5 severe cases, was treated with the hepatoprotective drugs only. Serum HBV DNA and TGF-β(1)were determined before and at 3 and 6 months during the treatment.
RESULTSEntecavir treatment reduced serum HBV DNA load in all the cases in entecavir group, and the difference was statistically significant between the levels measured at 3 and 6 months (P<0.05). The treatment also resulted in decreased serum TGF-β(1)levels in moderate and severe cases, and the severe cases showed a significant TGF-β(1)reduction after a 6-month treatment (P<0.05).
CONCLUSIONEntecavir can lower serum HBV DNA load levels in patients with chronic hepatitis B. Entecavir is also effective to reduce serum TGF-β(1)levels in moderate and severe cases, especially in the latter.
